Compare Flux Power Holdings Inc (FLUX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Sanofi SA — how do they compare? Flux Power Holdings Inc trades at $0.65 (market cap $11.23M), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 9287.6× Flux Power Holdings Inc's market cap, and Sanofi SA pays a 5.55% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | SNY | |
|---|---|---|
Market Cap | $11.23M | $104.30B |
Sector | Utilities | Health |
52-Week High | $6.66 | $52.34 |
52-Week Low | $0.51 | $41.33 |
Enterprise Value | $17.39M | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.5408, up 3.21% today, but technical indicators signal a bearish trend with selling pressure across moving averages. The company reported revenue of $66.43M in 2025 but a net loss of $6.67M, with profitability metrics like ROE at -52.27% reflecting operational challenges. Recent news highlights product launches like SkyEMS 3.0 and an upcoming earnings call on August 20, 2026.
Despite unanimous analyst buy ratings, FLUX faces significant risks from persistent losses and negative cash flow projections. Investment appeal hinges on execution of growth initiatives in lithium-ion storage, but high volatility and competitive pressures warrant caution for equity investors.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
